Dr Fraser Wright
Yposkesi, a European CDMO producing viral vectors (AAV and Lentivirus) for biopharmaceutical companies active in gene therapy, has announced the appointment of Dr Fraser Wright as Senior Advisor.
Dr Wright is a highly respected research scientist with in-depth knowledge of gene therapy vector manufacturing, whose experience includes leading process and analytical methods development as well as GMP manufacturing and quality systems. He will provide Yposkesi with scientific and technological advice and guidance on innovation in the production of viral vectors.
“We are proud to welcome Dr Wright as senior advisor,” said Alain Lamproye, CEO of Yposkesi. “His outstanding expertise and experience will reinforce our competitive edge through innovation. The scientific and technological innovation we are developing is geared to optimising efficiency in producing viral vectors at optimised cost, to the benefit of Yposkesi’s partners, clients and that of patients.”
With more than 20 years’ experience developing viral vector-based new biologic products in both industry and academia, Dr Wright joins Yposkesi in the midst of the company expanding its production capabilities and bolstering its market competitiveness. Yposkesi is currently doubling its building facilities at its European site from 50,000 sq ft to 100,000 sq ft.
“After decades of innovation, development and proof of concept in clinical studies, the gene and cell therapy field has now seen important product approvals in the EU and the US, fulfilling its promise to be a powerful new therapeutic paradigm for unmet medical needs. With its long-standing heritage and a foundation in gene therapy through Genethon, excellence in process development, vector manufacturing and quality systems, and state-of-the-art facilities, Yposkesi will continue to play a key role in advancing these transformative new medicines. I am pleased and sincerely honoured to join Yposkesi as senior advisor to help realise its important mission,” said Fraser Wright.
Since its founding in 2016, Yposkesi has advanced bioprocess developments, with significant success in developing an innovative process for large-scale cost-effective manufacturing of highly complex ATMPs (Advanced Therapy Medicinal Products).